This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional,
please visit our dedicated site for more information at www.beigene.co.uk
ONE BTK INHIBITOR: MANY POSSIBILITIES
A BTK inhibitor with a difference – Shaping the future of CLL treatment
This meeting was a live-streaming event in which expert clinicians discussed BRUKINSA®▼, a next-generation BTK inhibitor, as a treatment option for patients with CLL. The agenda and speaker information can be found below.
Topics included:
Clinical evidence supporting the use of BRUKINSA
Patient case studies
The use of BRUKINSA in the NHS
Agenda
Recordings
BRUKINSA® : A next-generation BTK inhibitor – Dr Talha Munir
Date of preparation: August 2023. 0823-BRU-PRC-010
BSH Guidelines: BRUKINSA® in CLL – Dr Renata Walewska
Date of preparation: September 2023. 0923-BRU-PRC-021
When should BRUKINSA® be your BTK inhibitor of choice? – Panel discussion and Q&A
Date of preparation: September 2023. 0923-BRU-PRC-020
Select an indication to learn more about BRUKINSA:
